The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Predictors of unsustained MRD negativity in transplant-eligible patients with multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible patients with multiple myeloma (MM). He notes that while many ongoing studies suggest MRD negativity could indicate stopping treatment after a few years of maintenance, some patients still progress early. Dr Paiva mentions four risk factors, indicating that if a patient presents with several of these, stopping treatment based on MRD negativity is not recommended. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
